

MF Strength
100 µg/act.
200 µg/act.
300 µg/act.
Mometasone Furoate Deposition (µg)
160.0
140.0
120.0
100.0
80.0
60.0
40.0
20.0
0.0
Inhaler
Throat
Stage 1
Stage 2
Stage 3
Stage 4
Stage 5
Stage 6
Stage 7
MOC
Impactor Stage (30LPM)

FIG. 1



◇MF ○FF △GP
MF FPM (µg/act.)
FF & GP FPM (µg/act.)
MF Strength (µg/act.)
160
120
80
40
0
40
30
20
10
0
50
100
150
200
250
300
350

FIG. 2



200 µg/act.
Drug
FF
GP
MF
Deposition (%)
40%
30%
20%
10%
0%
Inhaler
Throat
Stage 1
Stage 2
Stage 3
Stage 4
Stage 5
Stage 6
Stage 7
MOC
Impactor Stage (30 LPM)

FIG. 3B



100 µg/act.
Drug
FF
GP
MF
Deposition (%)
40%
30%
20%
10%
0%
Inhaler
Throat
Stage 1
Stage 2
Stage 3
Stage 4
Stage 5
Stage 6
Stage 7
MOC
Impactor Stage (30 LPM)

FIG. 3A



300 µg/act.
Drug
FF
GP
MF
Deposition (%)
40%
30%
20%
10%
0%
Inhaler
Throat
Stage 1
Stage 2
Stage 3
Stage 4
Stage 5
Stage 6
Stage 7
MOC
Impactor Stage (30 LPM)

FIG. 3C




FIG. 4A




FIG. 4B




FIG. 4C



35.0%
30.0%
25.0%
20.0%
15.0%
10.0%
5.0%
0.0%
% FF Recovered
Inhaler
Throat
1
2
3
4
5
6
7
MOC
Impactor Stage (30 LPM)
GFF, FF, FPM: 2.8µg, MMAD: 3.2µm, %FPF: 62.8%
BGF1, FF, FPM: 2.9µg, MMAD: 3.1µm, %FPF: 63.6%
BGF2, FF, FPM: 2.9µg, MMAD: 3.1µm, %FPF: 62.9%

FIG. 5



40.0%
35.0%
30.0%
25.0%
20.0%
15.0%
10.0%
5.0%
0.0%
% BD Recovered
Inhaler
Throat
1
2
3
4
5
6
7
MOC
Impactor Stage (30 LPM)
BGF3, BD, FPM: 21.8µg, MMAD: 3.4µm, %FPF: 58.5%
BGF1, BD, FPM: 87.3µg, MMAD: 3.4µm, %FPF: 58.1%
BGF2, BD, FPM: 87.9µg, MMAD: 3.4µm, %FPF: 58.4%

FIG. 6



2.50
2.00
1.50
1.00
0.50
0.00
GP (µg/act)
Inhaler
Throat
1
2
3
4
5
6
7
MOC
Impactor Stage (30 LPM)
GFF, GP, FPM: 4.1µg, MMAD: 3.0µm, %FPF: 64.1%
BGF1, GP, FPM: 4.5µg, MMAD: 3.0µm, %FPF: 63.7%
BGF2, GP, FPM: 4.3µg, MMAD: 3.1µm, %FPF: 63.1%

FIG. 7



40.0%
35.0%
30.0%
25.0%
20.0%
15.0%
10.0%
5.0%
0.0%
% BD Recovered
Inhaler
Throat
1
2
3
4
5
6
7
MOC
Impactor Stage (30 LPM)
BGF3, BD, FPM: 21.8µg, MMAD: 3.4µm, %FPF: 58.5%
BD Mono, BD, FPM: 88.9µg, MMAD: 3.6µm, %FPF: 57.2%
BFF, BD, FPM: 88.2µg, MMAD: 3.5µm, %FPF: 58.9%

FIG. 8



Mean Plasma Budesonide Concentration (pg/mL)
400
350
300
250
200
150
100
50
0
0
1
2
3
4
5
6
7
8
9
10
11
12
Time (hr)
Treatment
BGF 160
BGF 80
BGF MDI 40

FIG. 9



Mean Plasma Glycopyrronium Concentration (pg/mL)
0
1
2
3
4
5
6
7
8
9
10
Time (hr)
0
1
2
3
4
5
6
7
8
9
10
11
12
Treatment
BGF 160
BGF 40
BGF 80
GFF

FIG. 10



Mean Plasma Formoterol Fumarate Concentration (pg/mL)
0
1
2
3
4
5
6
7
8
9
10
Time (hr)
0
1
2
3
4
5
6
7
8
9
10
11
12
Treatment
BGF 160
GFF
BGF 80
BGF 40

FIG. 11